174 related articles for article (PubMed ID: 8646684)
1. Radiotherapy as a cisplatin-sensitizer in a resistant ovarian carcinoma cell line.
Siler DF; Wheeless CR; Dubin NH
Cancer; 1996 May; 77(9):1850-3. PubMed ID: 8646684
[TBL] [Abstract][Full Text] [Related]
2. Combined gamma-irradiation and subsequent cisplatin treatment in human squamous carcinoma cell lines sensitive and resistant to cisplatin.
Caney C; Singh G; Lukka H; Rainbow AJ
Int J Radiat Biol; 2004 Apr; 80(4):291-9. PubMed ID: 15204706
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
Gronlund B; Hansen HH; Høgdall C; Engelholm SA
Cancer; 2002 Oct; 95(8):1656-62. PubMed ID: 12365013
[TBL] [Abstract][Full Text] [Related]
4. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
5. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
6. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin and mild hyperthermia in radiosensitization to low dose rate irradiation in human ovarian carcinoma cells.
Raaphorst GP; Miao J; Ng CE
Anticancer Res; 1997; 17(5A):3469-72. PubMed ID: 9413189
[TBL] [Abstract][Full Text] [Related]
8. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
[TBL] [Abstract][Full Text] [Related]
9. Taxol sensitizes human ovarian cancer cells to radiation.
Steren A; Sevin BU; Perras J; Angioli R; Nguyen H; Guerra L; Koechli O; Averette HE
Gynecol Oncol; 1993 Feb; 48(2):252-8. PubMed ID: 8094062
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
[TBL] [Abstract][Full Text] [Related]
11. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine.
Louie KG; Behrens BC; Kinsella TJ; Hamilton TC; Grotzinger KR; McKoy WM; Winker MA; Ozols RF
Cancer Res; 1985 May; 45(5):2110-5. PubMed ID: 3986765
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
13. A high nuclear basal level of ERK2 phosphorylation contributes to the resistance of cisplatin-resistant human ovarian cancer cells.
Lee S; Yoon S; Kim DH
Gynecol Oncol; 2007 Feb; 104(2):338-44. PubMed ID: 17023032
[TBL] [Abstract][Full Text] [Related]
14. Palliative benefit of external-beam radiation in the management of platinum refractory epithelial ovarian carcinoma.
Gelblum D; Mychalczak B; Almadrones L; Spriggs D; Barakat R
Gynecol Oncol; 1998 Apr; 69(1):36-41. PubMed ID: 9570996
[TBL] [Abstract][Full Text] [Related]
15. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
[TBL] [Abstract][Full Text] [Related]
17. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
18. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
19. Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models.
Ewend MG; Williams JA; Tabassi K; Tyler BM; Babel KM; Anderson RC; Pinn ML; Brat DJ; Brem H
Cancer Res; 1996 Nov; 56(22):5217-23. PubMed ID: 8912860
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel and cisplatin sensitivity of ovarian carcinoma cell lines tested with the 96-well plate clonogenic assay.
Engblom P; Rantanen V; Kulmala J; Grènman S
Anticancer Res; 1996; 16(4A):1743-7. PubMed ID: 8712694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]